Profile data is unavailable for this security.
About the company
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.
- Revenue in USD (TTM)576.65m
- Net income in USD99.89m
- Incorporated2014
- Employees197.00
- LocationCollegium Pharmaceutical Inc100 Technology Center DrSTOUGHTON 02072-4710United StatesUSA
- Phone+1 (781) 713-3699
- Websitehttps://www.collegiumpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Bioservices Inc | 142.36m | -144.17m | 794.25m | 371.00 | -- | 13.54 | -- | 5.58 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Liquidia Corp | 14.84m | -112.11m | 862.67m | 136.00 | -- | 12.51 | -- | 58.13 | -1.57 | -1.57 | 0.2102 | 0.8208 | 0.0993 | -- | 4.04 | 109,117.60 | -75.00 | -55.02 | -87.85 | -62.69 | 69.52 | 82.18 | -755.46 | -474.59 | 5.78 | -29.47 | 0.578 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Phibro Animal Health Corp | 1.02bn | 2.42m | 907.69m | 1.94k | 376.39 | 3.54 | 23.52 | 0.8919 | 0.0595 | 0.0595 | 25.11 | 6.34 | 1.04 | 2.59 | 6.11 | 524,576.80 | 0.2473 | 3.93 | 0.3071 | 4.90 | 30.82 | 31.18 | 0.2374 | 3.77 | 1.64 | 1.76 | 0.6554 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| PetIQ Inc | 1.13bn | 13.19m | 926.89m | 1.93k | 80.90 | 3.56 | 16.46 | 0.8171 | 0.3802 | 0.3802 | 35.27 | 8.64 | 1.28 | 5.58 | 5.55 | 586,823.10 | 1.54 | -4.32 | 1.96 | -5.23 | 24.63 | 20.05 | 1.21 | -3.66 | 1.68 | 2.09 | 0.63 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Evolus Inc | 237.26m | -53.21m | 1.04bn | 304.00 | -- | 53.67 | -- | 4.37 | -0.9073 | -0.9073 | 4.02 | 0.3063 | 1.18 | 4.32 | 6.58 | 869,084.30 | -26.42 | -40.92 | -34.63 | -59.74 | 69.72 | 65.43 | -22.43 | -80.46 | 2.67 | -2.00 | 0.8623 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Innoviva Inc | 330.50m | 145.42m | 1.23bn | 112.00 | 11.90 | 1.85 | 6.64 | 3.72 | 1.65 | 1.65 | 4.15 | 10.64 | 0.2821 | 1.02 | 3.78 | 2,950,857.00 | 12.41 | 26.24 | 12.78 | 28.53 | 87.06 | -- | 44.00 | 76.84 | 11.40 | -- | 0.4019 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Collegium Pharmaceutical Inc | 576.65m | 99.89m | 1.25bn | 197.00 | 16.95 | 5.81 | 5.15 | 2.17 | 2.30 | 2.30 | 12.43 | 6.70 | 0.5087 | 8.14 | 3.28 | 2,927,173.00 | 8.81 | 2.79 | 14.58 | 4.80 | 61.94 | 50.88 | 17.32 | 5.16 | 1.04 | 3.69 | 0.7185 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| ANI Pharmaceuticals Inc | 538.95m | 22.95m | 1.27bn | 642.00 | 50.78 | 2.79 | 14.91 | 2.36 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 95.15m | -106.22m | 1.31bn | 154.00 | -- | 18.61 | -- | 13.76 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 83.37m | -150.07m | 1.32bn | 244.00 | -- | 5.22 | -- | 15.79 | -4.43 | -4.43 | 2.43 | 6.63 | 0.2947 | -- | 5.36 | 341,696.70 | -53.05 | -31.56 | -60.10 | -33.82 | 92.50 | -- | -180.00 | -242.59 | 6.99 | -- | 0.221 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.41bn | 267.00 | -- | 3.72 | -- | 23.07 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Tilray Brands Inc | 788.94m | -244.98m | 1.52bn | 2.65k | -- | 0.4301 | -- | 1.93 | -0.3334 | -0.3334 | 1.06 | 4.14 | 0.185 | 2.50 | 8.40 | 297,714.00 | -5.22 | -- | -5.72 | -- | 28.31 | -- | -28.19 | -- | 1.42 | -0.9071 | 0.0963 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Harrow Inc | 154.15m | -33.58m | 1.65bn | 315.00 | -- | 28.17 | -- | 10.70 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.71bn | 497.00 | -- | -- | -- | 6.08 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
Data as of Sep 19 2024. Currency figures normalised to Collegium Pharmaceutical Inc's reporting currency: US Dollar USD
70.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.11m | 15.85% |
| Pacer Advisors, Inc.as of 30 Jun 2024 | 3.41m | 10.58% |
| Eventide Asset Management LLCas of 30 Jun 2024 | 2.63m | 8.18% |
| Rubric Capital Management LPas of 30 Jun 2024 | 2.33m | 7.24% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.28m | 7.07% |
| Principal Global Investors LLCas of 30 Jun 2024 | 1.68m | 5.22% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.53m | 4.75% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.38m | 4.28% |
| Invesco Advisers, Inc.as of 30 Jun 2024 | 1.28m | 3.98% |
| Fuller & Thaler Asset Management, Inc.as of 30 Jun 2024 | 1.19m | 3.70% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
